<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;utm_source=Chrome&amp;utm_campaign= pubmed- 2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6 +86293ac<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 13 日星期一 00:39:34 +0000</lastbuilddate><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>与常规治疗相比，SGLT2 抑制剂、GLP-1 受体激动剂和非类固醇 MRA 联合治疗对 2 型糖尿病和蛋白尿患者的估计终生心血管、肾脏和死亡率益处</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952217/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>背景：钠葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i)、胰高血糖素样肽 1 受体激动剂 (GLP-1 RA) 和非类固醇盐皮质激素受体拮抗剂 (MRA) Finerenone 均可单独降低心血管、肾脏和死亡率结果。患有 2 型糖尿病和蛋白尿的患者。然而，这些药物联合治疗的终生益处尚不清楚。方法：我们使用了 2 项 SGLT2i 试验（CANVAS 和 CREDENCE）、2 项非类固醇 MRA 试验的数据…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.067584。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>钠葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i)、胰高血糖素样肽 1 受体激动剂 (GLP-1 RA) 和非类固醇盐皮质激素受体拮抗剂 (MRA) Finerenone 均可单独降低心血管、肾脏和死亡率结果。患有 2 型糖尿病和白蛋白尿的患者。然而，这些药物联合治疗的终生获益尚不清楚。<b>方法：</b>我们使用了 2 项 SGLT2i 试验（CANVAS 和 CREDENCE）、2 项非类固醇 MRA 试验（FIDELIO-DKD 和 FigARO）的数据-DKD）和 8 个 GLP-1 RA 试验，评估联合治疗与传统治疗（肾素-血管紧张素系统阻断和传统危险因素控制）对心血管、肾脏和死亡率结果的相对影响。然后使用精算方法，我们估计了绝对风险SGLT2i、GLP-1 RA 和非甾体 MRA 联合治疗可减少 2 型糖尿病患者的病情，并通过对接受常规护理的参与者应用估计的联合治疗效果，至少适度增加白蛋白尿（尿白蛋白：肌酐比≥30 mg/g） CANVAS 和 CREDENCE<b>结果：</b>与传统治疗相比，SGLT2i、GLP-1 RA 和非类固醇 MRA 联合治疗与主要不良心血管事件 (MACE；非致命性心肌梗死) 的风险比为 0.65 (95% CI 0.55-0.76)。 ），非致命性中风或心血管死亡）。3 年内相应的估计绝对风险降低为 4.4% (95% CI 3.0-5.7)，需要治疗的人数为 23 (95% CI 18-33)。50开始联合治疗的 1 岁儿童，预计无 MACE 事件生存期为 21.1 年，而传统治疗为 17.9 年（延长了 3.2 年，95% CI 2.1-4.3）。预计无住院心力衰竭的生存期也会增加（ 3.2 年，95% CI 2.4-4.0）、CKD 进展（5.5 年，95% CI 4.0-6.7）、心血管死亡（2.2 年，95% CI 1.2-3.0）和全因死亡（2.4 年，95% CI） 1.4-3.4). 在假设联合治疗有 50% 附加效应的分析中，观察到无事件生存期的减弱但临床相关的增益，包括 MACE（2.4 年，95% CI 1.1-3.5）、CKD 进展（4.5 年，95 % CI 2.8-5.9),) 和全因死亡（1.8 年，95% CI 0.7-2.8）。<b>结论：</b>对于蛋白尿至少中度增加的 2 型糖尿病患者，联合治疗 SGLT2i、GLP-1 RA 和非类固醇 MRA 有可能在心血管和肾脏无事件生存率以及总体生存率方面带来相关收益。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952217/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37952217</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067584>10.1161/循环AHA.123.067584</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952217</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>布伦登·诺伊恩</dc:creator><dc:creator>希多·JL·赫尔斯平克</dc:creator><dc:creator>普里亚·瓦尔特</dc:creator><dc:creator>布赖恩·L·克拉吉特</dc:creator><dc:creator>罗伯特·弗莱彻</dc:creator><dc:creator>克莱尔·阿诺特</dc:creator><dc:creator>朱莉安娜·德·奥利维拉·科斯塔</dc:creator><dc:creator>迈克尔·奥·法尔斯特</dc:creator><dc:creator>萨莉-安妮·皮尔森</dc:creator><dc:creator>肯尼思·W·马哈菲</dc:creator><dc:creator>布鲁斯·尼尔</dc:creator><dc:creator>拉吉夫·阿加瓦尔</dc:creator><dc:creator>乔治·巴克里斯</dc:creator><dc:creator>弗拉多·佩尔科维奇</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>与常规治疗相比，SGLT2 抑制剂、GLP-1 受体激动剂和非类固醇 MRA 联合治疗对 2 型糖尿病和蛋白尿患者的估计终生心血管、肾脏和死亡率益处</dc:title><dc:identifier>下午:37952217</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067584</dc:identifier></item><item><title>不确定潜力的克隆造血可预测心律失常的发生</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>结论：CHIP 可能是心律失常的一个新的危险因素，表明它是心律失常预防和治疗的潜在调节目标。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 11 日：ehad670。doi：10.1093/eurheartj/ehad670。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：不确定潜能克隆造血 (CHIP) 是具有白血病前期突变的血细胞与年龄相关的扩张，与动脉粥样硬化性心血管疾病和心力衰竭相关。本研究旨在测试 CHIP 与新发心律失常的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：纳入没有普遍心律失常的英国生物银行参与者。共同主要研究结果是室上性心律失常、缓慢性心律失常和室性心律失常。次要结果是心脏骤停、心房颤动和任何心律失常。任何 CHIP [变异等位基因分数 (VAF)] 的关联使用多变量调整的 Cox 回归评估 CHIP 与心肌间质纤维化的关联 [使用心脏磁共振 (CMR) 测量 T1]也进行了测试。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：本研究包括 410 702 名参与者 [CHIP：n = 13 892 (3.4%)；大型 CHIP：n = 9191 (2.2%)]。任何大型 CHIP 均与 1.11 的多变量调整风险比相关 [95室上性心律失常的%置信区间 (CI) 1.04-1.18；P = .001] 和 1.13 (95% CI 1.05-1.22；P = .001)，1.09 (95% CI 1.01-1.19；P = .031) 和 1.13缓慢性心律失常为 (95% CI 1.03-1.25；P = .011)，室性心律失常为 1.16 (95% CI 1.00-1.34；P = .049) 和 1.22 (95% CI 1.03-1.45；P = .021)分别。关联与冠状动脉疾病和心力衰竭无关。心律失常亚型之间的关联也存在异质性，并且与心脏骤停的关联最强。基因特异性分析显示除 DNMT3A 之外的驱动基因之间的心律失常风险增加。大 CHIP 与 1.31 相关根据 CMR 检测，处于心肌纤维化前五分位的几率 (95% CI 1.07-1.59；P = .009)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：CHIP 可能是心律失常的一个新的危险因素，表明它是心律失常预防和治疗的潜在调节目标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37952204</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad670>10.1093/eurheartj/ehad670</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952204</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>阿特·舒尔曼斯</dc:creator><dc:creator>凯特琳·弗拉斯哈特</dc:creator><dc:creator>维克多·诺法尔</dc:creator><dc:creator>苏美杰玛·曹</dc:creator><dc:creator>麦斯巴·乌丁</dc:creator><dc:creator>中尾哲志</dc:creator><dc:creator>阿布舍克·尼鲁拉</dc:creator><dc:creator>马库斯·克拉奎斯特博士</dc:creator><dc:creator>拉谢尔·D·周</dc:creator><dc:creator>艾米·林</dc:creator><dc:creator>赛义德·穆罕默德·萨达塔加</dc:creator><dc:creator>金兰纳里</dc:creator><dc:creator>黄梅根</dc:creator><dc:creator>惠特尼霍恩斯比</dc:creator><dc:creator>史蒂文·卢比茨</dc:creator><dc:creator>克里斯蒂·巴兰坦</dc:creator><dc:creator>悉达多贾斯瓦尔</dc:creator><dc:creator>彼得·利比</dc:creator><dc:creator>本杰明·艾伯特</dc:creator><dc:creator>亚历山大·G·比克</dc:creator><dc:creator>帕特里克·埃利诺</dc:creator><dc:creator>普拉迪普·纳塔拉詹</dc:creator><dc:creator>迈克尔·C·霍尼伯格</dc:creator><dc:date>2023-11-12</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>不确定潜力的克隆造血可预测心律失常的发生</dc:title><dc:identifier>下午:37952204</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad670</dc:identifier></item><item><title>袋阀面罩通气和院外心脏骤停的生存率：一项多中心研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>背景：很少有研究在气道放置前的早期心肺复苏 (CPR) 过程中测量通气量。复苏指南建议每 30 次胸外按压后暂停一次以提供通气。胸外按压提前暂停期间提供的气囊-瓣膜-面罩通气的有效性尚不清楚我们试图确定：(1) 30:2 心肺复苏过程中球囊-瓣膜-面罩通气导致肺充气的发生率；(2) 通气与……的关联</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.065561。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>很少有研究在气道放置前的早期心肺复苏 (CPR) 过程中测量通气量。复苏指南建议每 30 次胸外按压后暂停一次以提供通气。胸外按压提前暂停期间提供的气囊-瓣膜-面罩通气的有效性尚不清楚我们试图确定：(1) 30:2 心肺复苏过程中使用球囊-瓣膜-面罩通气时肺充气的发生率；(2) 通气与院外心脏骤停后结果的关系。<b>方法：</b>我们研究了患者复苏结果联盟 CCC 研究（在院外心脏骤停患者中进行连续按压与标准心肺复苏试验）的 6 个地点的院外心脏骤停患者。我们分析了分配到 30:2 CPR 组的患者，用心脏除颤器/监护仪记录≥2分钟的胸部生物阻抗信号。可检测的通气波形被定义为生物阻抗幅度≥0.5Ω（对应于≥250mL V <sub>T</sub> ）和持续时间≥1秒。我们定义了胸外按压暂停作为胸外按压 3 至 15 秒的中断。我们比较了 2 组的通气发生率和结果：通气波形出现 &lt;50% 暂停的患者（第 1 组）与波形出现 ≥50% 暂停的患者（第 1 组）第 2 组).<b>结果：</b> 1976 名患者中，平均年龄为 65 岁；66% 为男性。从开始胸外按压到高级气道放置，30:2 CPR 的平均±SD 持续时间为 9.8±4.9 分钟。在此期间，我们确定了 26861 次胸外按压暂停；60% 的患者在 &lt;50% 的暂停中出现通气波形（第 1 组，n=1177），40% 在 ≥50% 的暂停中出现通气波形（第 2 组，n= 799） ）。第 1 组每位患者平均有 12 次暂停和 2 次通气，而第 2 组每位患者有 12 次暂停和 12 次通气。第 2 组的院前自主循环恢复率较高（40.7% 对比 25.2%； <i>P</i> &lt; 0.0001） ）、出院生存率（13.5% 对比 4.1%； <i>P</i> &lt;0.0001）以及神经系统预后良好的生存率（10.6% 对比 2.4%； <i>P</i> &lt;0.0001）。在调整混杂因素后，这些关联仍然存在。<b>结论：</b>在这项研究中，在 30:2 心肺复苏过程中，气囊-瓣膜-面罩通气很少发生肺充气。≥50% 的暂停时间中，肺充气与自主循环恢复改善、生存以及具有良好神经学结果的生存有关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37952192</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065561>10.1161/CIRCULATIONAHA.123.065561</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952192</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>艾哈迈德·H·伊德里斯</dc:creator><dc:creator>伊丽莎白·阿拉门迪·埃塞纳罗</dc:creator><dc:creator>布赖恩·勒鲁</dc:creator><dc:creator>哈比尔·贾雷吉贝蒂亚</dc:creator><dc:creator>杨贝蒂</dc:creator><dc:creator>莎拉·谢弗</dc:creator><dc:creator>玛丽·P·张</dc:creator><dc:creator>汤姆·雷</dc:creator><dc:creator>彼得·库登丘克</dc:creator><dc:creator>吉姆·克里斯滕森</dc:creator><dc:creator>克里斯蒂安·瓦扬古</dc:creator><dc:creator>克利夫顿·W·卡拉威</dc:creator><dc:creator>大卫·萨尔西多</dc:creator><dc:creator>乔纳斯·卡森</dc:creator><dc:creator>詹妮弗·布莱克伍德</dc:creator><dc:creator>亨利·王</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>袋阀面罩通气和院外心脏骤停的生存率：一项多中心研究</dc:title><dc:identifier>下午:37952192</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065561</dc:identifier></item><item><title>直接口服抗凝剂预防设备检测到的心房颤动患者中风：NOAH-AFNET 6 和 ARTESiA 试验的研究级荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>背景：设备检测到的心房颤动 (AF)（也称为亚临床 AF 或心房高频率发作）是植入心律设备患者的常见症状，并且与缺血性中风风险增加相关。口服抗凝药物是否有效方法：我们对 MEDLINE 和 Embase 进行了系统评价，以进行随机试验，比较口服抗凝剂与抗血小板药物或不进行抗血栓治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.067512。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>设备检测到的心房颤动 (AF)（也称为亚临床 AF 或心房高频率发作）是植入心律设备患者的常见症状，并且与缺血性中风风险增加相关。口服抗凝药物是否有效<b>方法：</b>我们对 MEDLINE 和 Embase 进行了系统评价，以进行随机试验，比较口服抗凝剂与抗血小板药物或不进行抗血栓治疗的成人患者，这些患者患有由起搏器、植入式心脏复律除颤器记录的设备检测到的房颤，心脏再同步治疗装置或植入式心脏监护仪。我们使用随机效应模型进行荟萃分析，并使用 GRADE 框架对证据质量进行评级。该评论是预先注册的 (PROSPERO CRD42023463212)。<b>结果：</b>从 785 个独特的引用中，我们确定了两项具有相关临床结果数据的随机试验；NOAH-AFNET 6（2,536 名受试者）评估了艾多沙班，ARTESiA（4,012 名受试者）评估了阿哌沙班。荟萃分析表明，口服抗凝药物可减少缺血性中风（相对风险 [RR] 0.68, 95） ％置信区间[CI] 0.50-0.92；高质量证据）。两项试验的结果是一致的（异质性的 I <sup>2</sup>统计=0%）。口服抗凝药还减少了心血管死亡、全因中风、外周动脉栓塞、心肌梗死或肺栓塞（RR 0.85，95% CI 0.73-1.00，I <sup>2</sup> =0%；中等质量证据）。心血管死亡没有减少（RR 0.95，95% CI 0.76-1.17， I <sup>2</sup> =0%；中等质量证据）或全因死亡率（RR 1.08，95% CI 0.96-1.21 I <sup>2</sup> =0%；中等质量证据）。口服抗凝药增加大出血（RR 1.62，95% CI 1.05-2.5 <sup>I²</sup> =61%；高质量证据）。<b>结论：</b> NOAH-AFNET 6 和 ARTESiA 试验的结果相互一致。这两个大型随机试验的荟萃分析提供了口服抗凝药物的高质量证据与艾多沙班或阿哌沙班联合使用可降低设备检测到的 AF 患者中风的风险，并增加大出血的风险。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37952187</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067512>10.1161/循环AHA.123.067512</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952187</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>威廉·F·麦金太尔</dc:creator><dc:creator>亚历山大·本茨</dc:creator><dc:creator>尼娜·贝歇尔</dc:creator><dc:creator>杰弗里·希利</dc:creator><dc:creator>克里斯托弗·B·格兰杰</dc:creator><dc:creator>莉娜·里瓦德</dc:creator><dc:creator>约翰·卡姆</dc:creator><dc:creator>安德烈亚斯·戈特</dc:creator><dc:creator>安东尼娅·扎普夫</dc:creator><dc:creator>马可·阿林斯</dc:creator><dc:creator>斯图尔特·J·康诺利</dc:creator><dc:creator>保卢斯·基希霍夫</dc:creator><dc:creator>雷纳托·D·洛佩斯</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>直接口服抗凝剂预防设备检测到的心房颤动患者中风：NOAH-AFNET 6 和 ARTESiA 试验的研究级荟萃分析</dc:title><dc:identifier>下午：37952187</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067512</dc:identifier></item><item><title>索马鲁肽对射血分数保留且肥胖的心力衰竭患者的症状、功能和生活质量的影响：STEP-HFpEF 试验的预设分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>背景：射血分数保留 (HFpEF) 和肥胖的心力衰竭 (HF) 患者的症状和功能障碍负担较重，生活质量较差。在 STEP-HFpEF 试验中，每周一次 2.4 mg 索马鲁肽可改善症状，身体限制和运动功能，并减少炎症和体重。这项预先指定的分析研究了索马鲁肽对堪萨斯州范围内主要和验证性次要终点的影响…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.067505。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>射血分数保留 (HFpEF) 和肥胖的心力衰竭 (HF) 患者的症状和功能障碍负担较重，生活质量较差。在 STEP-HFpEF 试验中，每周一次 2.4 mg 索马鲁肽可改善症状，这项预先指定的分析调查了索马鲁肽对堪萨斯城心肌病问卷 (KCCQ) 基线评分范围内的主要和验证性次要终点的影响；以及对所有关键总结和体重的影响。<b>方法：</b> STEP-HFpEF 将 529 名有症状 HF、EF ≥ 45% 且 BMI ≥ 30 kg/m <sup>2</sup>的参与者随机分配至每周一次的索马鲁肽 2.4 mg 或安慰剂，持续 52 周。双重主要终点是 KCCQ- 的变化临床总结评分 (CSS) 和体重。确认性次要终点包括 6 分钟步行距离 (6MWD) 的变化、分层复合终点（死亡、心力衰竭事件以及 KCCQ-CSS 和 6MWD 的变化）以及 C-变化患者在基线时按 KCCQ-CSS 三分位数进行分层。在这些亚组中检查了索马鲁肽对主要、确认性次要和选择探索性终点 (NTproBNP) 的影响。索马鲁肽对其他 KCCQ 领域的影响（总症状评分 [包括症状负担和结果<b>：</b>三分位数的基线中位 KCCQ-CSS 分别为 37、59 和 77 分。索马鲁肽持续改善 KCCQ 三分位数 1-3 的主要终点（估计治疗差异 (ETD;95% CI)：对于 KCCQ-CSS，10.7 (5.4 ,16.1), 8.1 (2.7,13.4), 4.6 (-0.6,9.9) 分；对于体重， - 11 (-13.2,-8.8), -9.4 (-11.5,-7.2), -11.8 (-14.0, -9.6)%，分别；P<i>相互作用</i>= 0.28 和 0.29，分别）；对于确认性次要和探索性终点也观察到相同的情况（所有 P<i>相互作用</i>>;0.1）。接受索马鲁肽治疗的患者在所有关键 KCCQ 领域都经历过这种情况（ETD：6.7）跨改善领域为 -9.6 分；所有<i>P</i> ≤ 0.001）。与安慰剂治疗患者相比，接受索马鲁肽治疗的患者在所有 KCCQ 领域中经历了至少 5、10、15 和 20 分的改善（优势比：1.6- 2.9 跨领域； <i>P</i> &lt; 0.05）。<b>结论：</b>在 HFpEF 和肥胖患者中，无论基线健康状况如何，索马鲁肽都能显着改善 HF 相关症状、身体限制、运动功能、炎症、体重和 NTproBNP。索马鲁肽扩展到所有关键的 KCCQ 领域。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37952180</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067505>10.1161/CIRCULATIONAHA.123.067505</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952180</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>苏博德·维尔玛</dc:creator><dc:creator>巴里·博洛格</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>梅兰妮·J·戴维斯</dc:creator><dc:creator>托马斯·乔恩·詹森</dc:creator><dc:creator>索伦·拉斯穆森</dc:creator><dc:creator>彼得·埃尔兰·马斯特兰德</dc:creator><dc:creator>马克·皮特里</dc:creator><dc:creator>桑吉夫·J·沙阿</dc:creator><dc:creator>伊藤浩</dc:creator><dc:creator>莫滕·舒</dc:creator><dc:creator>沃伊捷赫·梅列诺夫斯基</dc:creator><dc:creator>沃尔特·阿巴亚拉特纳</dc:creator><dc:creator>达兰·W·基茨曼</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>索马鲁肽对射血分数保留且肥胖的心力衰竭患者的症状、功能和生活质量的影响：STEP-HFpEF 试验的预设分析</dc:title><dc:identifier>下午:37952180</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067505</dc:identifier></item><item><title>射血分数轻度降低或保留的心力衰竭患者使用达格列净后估计肾小球滤过率下降：DELIVER 随机临床试验的预先指定二次分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952176/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在接受达格列净治疗的 HFmrEF 或 HFpEF 患者中，初始 eGFR 下降很常见，但与随后的心血管或肾脏事件风险无关。这些数据强化了临床指导，即不应因初始 eGFR 下降而中断或终止 SGLT2is。 eGFR 下降。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 11 月 12 日。doi：10.1001/jamacardio.2023.4664。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：在开始使用钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 后，估计肾小球滤过率 (eGFR) 预计会出现初始下降，并且已在糖尿病、慢性肾病和心力衰竭患者中观察到这一情况。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：研究参加达格列净改善射血分数保留性心力衰竭患者生活评价（DELIVER）的射血分数轻度降低（HFmrEF）或射血分数保留（HFpEF）心力衰竭患者的 eGFR 初始变化的影响。 ） 审判。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这是对 DELIVER 随机临床试验结果的预先指定分析，该试验是一项国际多中心研究，对象为 EF 大于 40% 且 eGFR 大于或等于 25 的患者。DELIVER 试验进行从2018年8月到2022年3月。当前预定研究的数据是在2023年2月到2023年10月期间进行分析的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：达格列净，每天 10 毫克，或安慰剂。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：在这项预先指定的分析中，比较了达格列净和安慰剂之间初始 eGFR 下降的频率（基线至第 1 个月）。根据基线 eGFR 调整的 Cox 模型和已建立的预后因素适合估计初始 eGFR 的关联。心血管（心血管死亡或心力衰竭事件）和肾脏（eGFR 下降≥50%、eGFR&lt;15 或透析、肾脏原因死亡）结果的下降，以第 1 个月为标志，按糖尿病分层。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：对 5788 名参与者（平均 [SD] 年龄，72 [10] 岁；3253 名男性 [56%]）的研究数据进行了分析。eGFR 水平从基线到第 1 个月的中位 (IQR) 变化为 -1 (-6安慰剂组为 -4 至 5），达格列净组为 -4（-9 至 1）（差异，-3；P &lt; .001）。与安慰剂组相比，分配至达格列净组的患者中，初始 eGFR 下降超过 10% 的比例较高（1144 名患者） 2892 [40%] 对比 2896 中的 737 [25%]；比值比，1.9；95% CI，1.7-2.1；P 差异 &lt;.001)。初始 eGFR 下降大于 10%（对比 ≤10%）与随机接受安慰剂的患者主要心血管结局风险较高相关（调整后风险比[aHR]，1.33；95% CI，1.10-1.62），但与随机接受达格列净的患者无关（aHR，0.90；95% CI，0.74） -1.09；交互作用 P = .01)。当考虑初始 eGFR 下降的替代阈值并作为连续测量进行分析时，观察到类似的关联。大于 10% 的初始 eGFR 下降与随后的不良肾脏复合结果无关在达格列净治疗的患者中（aHR，0.94；95% CI，0.49-1.82）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在接受达格列净治疗的 HFmrEF 或 HFpEF 患者中，初始 eGFR 下降很常见，但与随后的心血管或肾脏事件风险无关。这些数据强化了临床指导，即不应因初始 eGFR 下降而中断或终止 SGLT2is。 eGFR 下降。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT03619213。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952176/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37952176</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.4664>10.1001/jamacardio.2023.4664</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952176</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>芬尼安·R·麦考斯兰</dc:creator><dc:creator>布赖恩·L·克拉吉特</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:creator>阿克谢·德赛</dc:creator><dc:creator>帕迪普·琼德</dc:creator><dc:creator>奥利瓦尔德尼</dc:creator><dc:creator>詹姆斯·C·方</dc:creator><dc:creator>鲁道夫·德波尔</dc:creator><dc:creator>基兰·F·多彻蒂</dc:creator><dc:creator>阿德里安·埃尔南德斯</dc:creator><dc:creator>西尔维奥·因祖奇</dc:creator><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>卡罗琳·SP·林</dc:creator><dc:creator>费利佩·马丁内斯</dc:creator><dc:creator>何塞·科尔·萨莱瓦</dc:creator><dc:creator>玛蒂娜·麦克格拉斯</dc:creator><dc:creator>桑吉夫·J·沙阿</dc:creator><dc:creator>苏博德·维尔玛</dc:creator><dc:creator>安娜·玛丽亚·朗基尔德</dc:creator><dc:creator>马格努斯·彼得森</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:date>2023-11-12</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>射血分数轻度降低或保留的心力衰竭患者使用达格列净后估计肾小球滤过率下降：DELIVER 随机临床试验的预先指定二次分析</dc:title><dc:identifier>下午:37952176</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4664</dc:identifier></item><item><title>美国 25 至 64 岁成年人的心血管住院率和死亡率</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>结论：从 2008 年到 2019 年，美国年轻人因心血管疾病住院的人数出现了惊人的增长，而且居住在低收入和高收入社区的人之间的差距并没有缩小。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 11 日：ehad772。doi：10.1093/eurheartj/ehad772。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目标：自 2011 年以来，美国心​​血管死亡率的下降一直停滞不前。人们越来越担心这些模式反映了年轻人心血管健康状况的老化。然而，人们对美国急性心血管住院和死亡率的负担如何变化知之甚少。对 25-64 岁成年人心血管住院和死亡率的变化进行了总体评估和社区层面的收入评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用全国住院患者样本，确定 25-64 岁成年人中急性心肌梗死 (AMI)、心力衰竭和缺血性中风的年龄标准化年度住院率和住院死亡率。准泊松和准二项回归模型适合比较居住在低收入和高收入社区的个人之间的结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：2008 年至 2019 年间，年轻人中 AMI 年龄标准化住院率从每 100,000 人 155.0 (95% CI 154.6, 155.4) 增加至每 100,000 人 160.7 (160.3, 161.1)（绝对变化 +5.7 [5.0, 6.3]， p&lt;0.001）。心力衰竭住院率也增加（165.3 [164.8, 165.7] 至 225.3 [224.8, 225.8]，绝对变化+60.0 (59.3, 60.6)，p&lt;0.001），缺血性中风住院率也增加（76.3 [76.1, 76.7] ] 到 108.1 [107.8, 108.5]，绝对变化 +31.7 (31.2, 32.2)，p&lt;0.001)。在所有条件下，与高收入社区相比，居住在低收入社区的年轻人的住院率显着更高，并且存在差异组间死亡率并没有缩小。在研究期间，所有情况下的院内死亡率均有所下降。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：2008 年至 2019 年间，美国年轻人因心血管疾病住院的人数急剧增加，低收入和高收入社区居民之间的差距并未缩小。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37952173</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad772>10.1093/eurheartj/ehad772</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952173</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>尚塔尔·M·亨利</dc:creator><dc:creator>安德鲁·奥塞兰</dc:creator><dc:creator>赵年政</dc:creator><dc:creator>董华英</dc:creator><dc:creator>里希·K·瓦德拉</dc:creator><dc:date>2023-11-12</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>美国 25 至 64 岁成年人的心血管住院率和死亡率</dc:title><dc:identifier>下午：37952173</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad772</dc:identifier></item><item><title> “艰难而快速”的复苏指南可能需要一点“呼吸”空间</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952160/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.066071。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37952160</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066071>10.1161/CIRCULATIONAHA.123.066071</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952160</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>迈克尔·克里斯托弗·库尔兹</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>“艰难而快速”的复苏指南可能需要一点“呼吸”空间</dc:title><dc:identifier>下午：37952160</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066071</dc:identifier></item><item><title>生发中心输出表达高亲和力和低亲和力抗体的克隆多样化浆细胞群</title><link/>https://pubmed.ncbi.nlm.nih.gov/37951212/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>免疫或感染后，淋巴结中形成生发中心 (GC)，以促进抗体亲和力成熟以及记忆和浆细胞 (PC) 发育。PC 分化被认为涉及对表达最高亲和力抗原受体的 GC B 细胞的严格选择，但如何这在复杂的多克隆反应中发挥的作用尚不清楚。我们将时间谱系追踪与抗体表征结合起来，以获得流感感染期间 PC 发展的快照。GC... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 11 月 7 日：S0092-8674(23)01173-X. doi: 10.1016/j.cell.2023.10.022. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">免疫或感染后，淋巴结中形成生发中心 (GC)，以促进抗体亲和力成熟以及记忆和浆细胞 (PC) 发育。PC 分化被认为涉及对表达最高亲和力抗原受体的 GC B 细胞的严格选择，但如何复杂的多克隆反应期间的情况尚不清楚。我们将时间抗体谱系追踪与抗体表征结合起来，以获得流感感染期间 PC 发展的快照。GC 与 B 细胞克隆共同成熟，其亲和力跨越多个数量级；然而，每个克隆都会产生 PC具有相似的效率，包括弱结合物。在谱系内，PC选择不限于产生具有最高亲和力抗体的变体。分化通常与增殖扩展至相同PC的“节点”相关。免疫诱导的GC产生较少的PC，但仍然我们提出，产生低亲和力抗体 PC 反映了一种进化妥协，以促进不同的血清抗体反应。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37951212/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37951212</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.10.022>10.1016/j.cell.2023.10.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37951212</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator>阿德里安·斯普鲁蒙</dc:creator><dc:creator>安娜·罗德里格斯</dc:creator><dc:creator>西蒙·J·麦高恩</dc:creator><dc:creator>科林·班纳德</dc:creator><dc:creator>奥利弗·班纳德</dc:creator><dc:date>2023-11-11</dc:date><dc:source>细胞</dc:source><dc:title>生发中心输出表达高亲和力和低亲和力抗体的克隆多样化浆细胞群</dc:title><dc:identifier>下午：37951212</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.022</dc:identifier></item><item><title>年轻成人的复杂前纵隔肿块</title><link/>https://pubmed.ncbi.nlm.nih.gov/37950914/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231112193932&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 11 日。doi：10.1161/CIRCULATIONAHA.123.067585。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37950914/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950914</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067585>10.1161/CIRCULATIONAHA.123.067585</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37950914</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator>吉赛尔·亚历山德拉·苏罗-阿布鲁</dc:creator><dc:creator>宋莉莉</dc:creator><dc:creator>阿努什里·帕拉赫</dc:creator><dc:creator>布赖恩·戈什哈吉拉</dc:creator><dc:creator>托马斯·内兰</dc:creator><dc:creator>多琳·德法莉亚·叶</dc:creator><dc:creator>尹鹏鸿</dc:creator><dc:creator>丹妮尔·B·卡梅伦</dc:creator><dc:creator>乔丹·P·布鲁姆</dc:creator><dc:date>2023-11-11</dc:date><dc:source>循环</dc:source><dc:title>年轻成人的复杂前纵隔肿块</dc:title><dc:identifier>下午:37950914</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067585</dc:identifier></item><item><title> Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> Background: Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling. Methods: In this prospective, randomized, open-label, blinded endpoint trial, in a single... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067597. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling. <b>Methods:</b> In this prospective, randomized, open-label, blinded endpoint trial, in a single UK hospital, 220 women were randomly assigned 1:1 to self-monitoring with research physician-optimized antihypertensive titration, or usual postnatal care from primary care physician and midwife. Participants were aged 18 years or over, with pre-eclampsia or gestational hypertension, requiring antihypertensives on hospital discharge postnatally. Pre-specified secondary cardiac imaging outcomes were recorded by echocardiography around delivery, and again at blood pressure primary outcome assessment, around nine months postpartum, when cardiovascular magnetic resonance was also performed. <b>Results:</b> 187 women (101 intervention; 86 usual care) underwent echocardiography at baseline and follow up, at a mean 258+/-14.6 days postpartum, of which 174 (93 intervention; 81 usual care) also had cardiovascular magnetic resonance at follow up. Relative wall thickness by echocardiography was 0.06 (95% CI0.07 to 0.05, P=&lt;0.001) lower in the intervention group between baseline and follow up, and cardiovascular magnetic resonance at follow up demonstrated a lower left ventricular mass (-6.37g/m <sup>2</sup> (95% CI -7.99 to -4.74, P&lt;0.001), end diastolic volume (-3.87ml/m <sup>2</sup> , 95% CI -6.77 to -0.98, P=0.009) and end systolic volume (-3.25ml/m <sup>2</sup> , 95% CI 4.87 to -1.63, P &lt;0.001) and higher left and right ventricular ejection fraction by 2.6% (95% CI 1.3 to 3.9, P&lt;0.001) and 2.8% (95% CI 1.4 to 4.1, P&lt;0.001) respectively. Echocardiography assessed left ventricular diastolic function demonstrated a mean difference in average E/E&#39; of 0.52 (95% CI -0.97 to -0.07, P=0.024), and a reduction in left atrial volumes of -4.33ml/m <sup>2</sup> (95% CI -5.52 to -3.21, P=&lt;0.001) between baseline and follow up, when adjusted for baseline differences in measures. <b>Conclusions:</b> Short-term postnatal optimization of blood pressure control following hypertensive pregnancy, through self-monitoring and physician-guided antihypertensive titration, associates with long term changes in cardiovascular structure and function, in a pattern associated with more favorable cardiovascular outcomes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950907</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067597>10.1161/CIRCULATIONAHA.123.067597</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950907</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Jamie Kitt</dc:creator><dc:creator> Samuel Krasner</dc:creator><dc:creator> Logan Barr</dc:creator><dc:creator> Annabelle Frost</dc:creator><dc:creator> Katherine Tucker</dc:creator><dc:creator> Paul A Bateman</dc:creator><dc:creator> Katie Suriano</dc:creator><dc:creator> Yvonne Kenworthy</dc:creator><dc:creator> Winok Lapidaire</dc:creator><dc:creator> Miriam Lacharie</dc:creator><dc:creator> Rebecca Mills</dc:creator><dc:creator> Cristian Roman</dc:creator><dc:creator> Lucy Mackillop</dc:creator><dc:creator> Alexandra Cairns</dc:creator><dc:creator> Christina Aye</dc:creator><dc:creator> Vanessa Ferreira</dc:creator><dc:creator> Stefan Piechnik</dc:creator><dc:creator> Elena Lukaschuk</dc:creator><dc:creator> Basky Thilaganathan</dc:creator><dc:creator> Lucy C Chappell</dc:creator><dc:creator> Adam J Lewandowski</dc:creator><dc:creator> Richard J McManus</dc:creator><dc:creator> Paul Leeson</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> Circulation</dc:source><dc:title> Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study</dc:title><dc:identifier> pmid:37950907</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067597</dc:identifier></item><item><title> Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> Background: The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). Methods: Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high-risk for developing HF were identified using 1-step screening strategies: risk score... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). <b>Methods:</b> Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high-risk for developing HF were identified using 1-step screening strategies: risk score (WATCH-DM≥12); N-terminal pro-B-type natriuretic peptide (NT-proBNP;≥125 pg/mL); high-sensitivity cardiac troponin (hs-cTnT ≥14 ng/L, hs-cTnI≥31 ng/L); echocardiography-based diabetic cardiomyopathy (echo-DbCM; LA enlargement, LV hypertrophy, or diastolic dysfunction). High-risk participants were also identified using 2-step screening strategies with a second test to additionally identify residual risk among those deemed low-risk by the first test: WATCH-DM/NT-proBNP, NT-proBNP/hs-cTn, NT-proBNP/echo-DbCM. Across screening strategies, the proportion of HF events identified, 5-year number needed to treat (NNT <sup>5</sup> ) and number needed to screen (NNS <sup>5</sup> ) to prevent 1 HF event with an SGLT2i among high-risk participants, and cost of screening were estimated. <b>Results:</b> The initial study cohort included 6,293 participants (48.2% women), of which 77.7% without prevalent ASCVD were evaluated with different HF screening strategies. At 5-year follow-up, 6.2% of participants without ASCVD developed incident HF. The NNT <sup>5</sup> to prevent 1 HF event with an SGLT2i among participants without ASCVD was 43 (95%CI, 29-72). In the cohort without ASCVD, high-risk participants identified using 1-step screening strategies had low NNT <sup>5</sup> (22 for NT-proBNP to 37 for echo-DbCM). However, a substantial proportion of HF events occurred among participants identified as low-risk using 1-step screening approaches (29% for echo-DbCM to 47% for hs-cTn). 2-step screening strategies captured most HF events (75-89%) in the high-risk subgroup with a comparable NNT <sup>5</sup> as the 1-step screening approaches (30-32). The NNS <sup>5</sup> to prevent 1 HF event was similar across 2-step screening strategies (45-61). However, the number of tests and associated costs were lowest for WATCH-DM/NT-proBNP ($1,061) compared with other 2-step screening strategies (NT-proBNP/hs-cTn: $2,894; NT-proBNP/echo-DbCM: $16,358). <b>Conclusions:</b> Selective NT-proBNP testing based on the WATCH-DM score efficiently identified a high-risk primary prevention population with diabetes expected to derive marked absolute benefits from SGLT2i to prevent HF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950893</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067530>10.1161/CIRCULATIONAHA.123.067530</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950893</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Kershaw V Patel</dc:creator><dc:creator> Matthew W Segar</dc:creator><dc:creator> David C Klonoff</dc:creator><dc:creator> Muhammad Shahzeb Khan</dc:creator><dc:creator> Muhammad Shariq Usman</dc:creator><dc:creator> Carolyn SP Lam</dc:creator><dc:creator> Subodh Verma</dc:creator><dc:creator> Andrew P DeFilippis</dc:creator><dc:creator> Khurram Nasir</dc:creator><dc:creator> Stephan JL Bakker</dc:creator><dc:creator> B Daan Westenbrink</dc:creator><dc:creator> Robin PF Dullaart</dc:creator><dc:creator> Javed Butler</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:creator> Ambarish Pandey</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> Circulation</dc:source><dc:title> Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis</dc:title><dc:identifier> pmid:37950893</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067530</dc:identifier></item><item><title> Device-measured physical activity and cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS) consortium</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Compositional data analyses revealed a distinct hierarchy of behaviours. Moderate-vigorous physical activity demonstrated the strongest, most time-efficient protective associations with cardiometabolic outcomes. Theoretical benefits from reallocating SB into sleep, standing, or LIPA required substantial changes in daily activity. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 10:ehad717. doi: 10.1093/eurheartj/ehad717. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Physical inactivity, sedentary behaviour (SB), and inadequate sleep are key behavioural risk factors of cardiometabolic diseases. Each behaviour is mainly considered in isolation, despite clear behavioural and biological interdependencies. The aim of this study was to investigate associations of five-part movement compositions with adiposity and cardiometabolic biomarkers. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Cross-sectional data from six studies (n = 15 253 participants; five countries) from the Prospective Physical Activity, Sitting and Sleep consortium were analysed. Device-measured time spent in sleep, SB, standing, light-intensity physical activity (LIPA), and moderate-vigorous physical activity (MVPA) made up the composition. Outcomes included body mass index (BMI), waist circumference, HDL cholesterol, total:HDL cholesterol ratio, triglycerides, and glycated haemoglobin (HbA1c). Compositional linear regression examined associations between compositions and outcomes, including modelling time reallocation between behaviours. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The average daily composition of the sample (age: 53.7 ± 9.7 years; 54.7% female) was 7.7 h sleeping, 10.4 h sedentary, 3.1 h standing, 1.5 h LIPA, and 1.3 h MVPA. A greater MVPA proportion and smaller SB proportion were associated with better outcomes. Reallocating time from SB, standing, LIPA, or sleep into MVPA resulted in better scores across all outcomes. For example, replacing 30 min of SB, sleep, standing, or LIPA with MVPA was associated with -0.63 (95% confidence interval -0.48, -0.79), -0.43 (-0.25, -0.59), -0.40 (-0.25, -0.56), and -0.15 (0.05, -0.34) kg/m2 lower BMI, respectively. Greater relative standing time was beneficial, whereas sleep had a detrimental association when replacing LIPA/MVPA and positive association when replacing SB. The minimal displacement of any behaviour into MVPA for improved cardiometabolic health ranged from 3.8 (HbA1c) to 12.7 (triglycerides) min/day. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Compositional data analyses revealed a distinct hierarchy of behaviours. Moderate-vigorous physical activity demonstrated the strongest, most time-efficient protective associations with cardiometabolic outcomes. Theoretical benefits from reallocating SB into sleep, standing, or LIPA required substantial changes in daily activity.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950859</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad717>10.1093/eurheartj/ehad717</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950859</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Joanna M Blodgett</dc:creator><dc:creator> Matthew N Ahmadi</dc:creator><dc:creator> Andrew J Atkin</dc:creator><dc:creator> Sebastien Chastin</dc:creator><dc:creator> Hsiu-Wen Chan</dc:creator><dc:creator> Kristin Suorsa</dc:creator><dc:creator> Esmee A Bakker</dc:creator><dc:creator> Pasan Hettiarcachchi</dc:creator><dc:creator> Peter J Johansson</dc:creator><dc:creator> Lauren B Sherar</dc:creator><dc:creator> Vegar Rangul</dc:creator><dc:creator> Richard M Pulsford</dc:creator><dc:creator> Gita Mishra</dc:creator><dc:creator> Thijs MH Eijsvogels</dc:creator><dc:creator> Sari Stenholm</dc:creator><dc:creator> Alun D Hughes</dc:creator><dc:creator> Armando M Teixeira-Pinto</dc:creator><dc:creator> Ulf Ekelund</dc:creator><dc:creator> I Min Lee</dc:creator><dc:creator> Andreas Holtermann</dc:creator><dc:creator> Annemarie Koster</dc:creator><dc:creator> Emmanuel Stamatakis</dc:creator><dc:creator> Mark Hamer</dc:creator><dc:creator> ProPASS Collaboration</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> Device-measured physical activity and cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS) consortium</dc:title><dc:identifier> pmid:37950859</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad717</dc:identifier></item><item><title> Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: The C3PO NLP model developed within 1 health care system identified HF events with good agreement relative to the gold-standard CEC in an external multicenter clinical trial. Fine-tuning the model improved agreement and approximated human reproducibility. Further study is needed to determine whether NLP will improve the efficiency of future multicenter clinical trials by identifying clinical events at scale. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 11:e234859. doi: 10.1001/jamacardio.2023.4859. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: The gold standard for outcome adjudication in clinical trials is medical record review by a physician clinical events committee (CEC), which requires substantial time and expertise. Automated adjudication of medical records by natural language processing (NLP) may offer a more resource-efficient alternative but this approach has not been validated in a multicenter setting. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To externally validate the Community Care Cohort Project (C3PO) NLP model for heart failure (HF) hospitalization adjudication, which was previously developed and tested within one health care system, compared to gold-standard CEC adjudication in a multicenter clinical trial. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of the Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) trial, which compared 2 influenza vaccines in 5260 participants with cardiovascular disease at 157 sites in the US and Canada between September 2016 and January 2019. Analysis was performed from November 2022 to October 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> EXPOSURES: Individual sites submitted medical records for each hospitalization. The central INVESTED CEC and the C3PO NLP model independently adjudicated whether the cause of hospitalization was HF using the prepared hospitalization dossier. The C3PO NLP model was fine-tuned (C3PO + INVESTED) and a de novo NLP model was trained using half the INVESTED hospitalizations. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: Concordance between the C3PO NLP model HF adjudication and the gold-standard INVESTED CEC adjudication was measured by raw agreement, κ, sensitivity, and specificity. The fine-tuned and de novo INVESTED NLP models were evaluated in an internal validation cohort not used for training. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 4060 hospitalizations in 1973 patients (mean [SD] age, 66.4 [13.2] years; 514 [27.4%] female and 1432 [72.6%] male]), 1074 hospitalizations (26%) were adjudicated as HF by the CEC. There was good agreement between the C3PO NLP and CEC HF adjudications (raw agreement, 87% [95% CI, 86-88]; κ, 0.69 [95% CI, 0.66-0.72]). C3PO NLP model sensitivity was 94% (95% CI, 92-95) and specificity was 84% (95% CI, 83-85). The fine-tuned C3PO and de novo NLP models demonstrated agreement of 93% (95% CI, 92-94) and κ of 0.82 (95% CI, 0.77-0.86) and 0.83 (95% CI, 0.79-0.87), respectively, vs the CEC. CEC reviewer interrater reproducibility was 94% (95% CI, 93-95; κ, 0.85 [95% CI, 0.80-0.89]). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: The C3PO NLP model developed within 1 health care system identified HF events with good agreement relative to the gold-standard CEC in an external multicenter clinical trial. Fine-tuning the model improved agreement and approximated human reproducibility. Further study is needed to determine whether NLP will improve the efficiency of future multicenter clinical trials by identifying clinical events at scale.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950744</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10640703/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">PMC10640703</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4859>10.1001/jamacardio.2023.4859</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950744</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Jonathan W Cunningham</dc:creator><dc:creator> Pulkit Singh</dc:creator><dc:creator> Christopher Reeder</dc:creator><dc:creator> Brian Claggett</dc:creator><dc:creator> Pablo M Marti-Castellote</dc:creator><dc:creator> Emily S Lau</dc:creator><dc:creator> Shaan Khurshid</dc:creator><dc:creator> Puneet Batra</dc:creator><dc:creator> Steven A Lubitz</dc:creator><dc:creator> Mahnaz Maddah</dc:creator><dc:creator> Anthony Philippakis</dc:creator><dc:creator> Akshay S Desai</dc:creator><dc:creator> Patrick T Ellinor</dc:creator><dc:creator> Orly Vardeny</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:creator> Jennifer E Ho</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial</dc:title><dc:identifier> pmid:37950744</dc:identifier><dc:identifier> pmc:PMC10640703</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4859</dc:identifier></item><item><title> Innovation in Event Adjudication-Human vs Machine</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 11. doi: 10.1001/jamacardio.2023.4900. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950739/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950739</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4900>10.1001/jamacardio.2023.4900</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950739</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Kenneth W Mahaffey</dc:creator><dc:creator> C Michael Gibson</dc:creator><dc:creator> Renato D Lopes</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Innovation in Event Adjudication-Human vs Machine</dc:title><dc:identifier> pmid:37950739</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4900</dc:identifier></item><item><title> Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS)</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> Background: Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization when compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy (CRT). We sought to compare the occurrence of sustained ventricular tachycardia or ventricular fibrillation (VT/VF) and new onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. Methods: This... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067465. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization when compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy (CRT). We sought to compare the occurrence of sustained ventricular tachycardia or ventricular fibrillation (VT/VF) and new onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. <b>Methods:</b> This International Collaborative LBBAP Study (I-CLAS) included patients with LVEF≤35% who underwent BVP or LBBAP for CRT between Jan 2018 to June 2022 at 15 centers. We performed propensity score matched (PS) analysis of LBBAP and BVP in a 1:1 ratio. We assessed the incidence of VT/VF and new-onset AF among patients with no prior history of AF. Time to sustained VT/VF and time to new-onset AF was analyzed using Cox proportional hazards survival model. <b>Results:</b> Among 1778 patients undergoing CRT (981-BVP, 797-LBBAP), PS matched 1414 patients (PS-BVP:707, PS-LBBAP:707). The occurrence of VT/VF was significantly lower with LBBAP compared with BVP (4.2% vs 9.3%;HR 0.46;95%CI 0.29-0.74;p&lt;0.001). The incidence of VT storm (>;3 episodes in 24 hours) was also significantly lower with LBBAP compared with BVP (0.8% vs 2.5%;p=0.013). Among 299 patients with CRT-pacemakers (BVP-111, LBBAP-188), VT/VF occurred in 8 patients in the BVP group vs. none in the LBBAP group (7.2% vs 0%;p&lt;0.001). In 1194 patients with no prior history of VT/VF or antiarrhythmic therapy (BVP-591, LBBAP-603), the occurrence of VT/VF was significantly lower with LBBAP compared with BVP (3.2% vs 7.3%;HR 0.46;95%CI 0.26-0.81;p=0.007). Among patients with no prior history of AF (n=890), the occurrence of new-onset AF >;30 seconds was significantly lower with LBBAP compared with BVP (2.8% vs 6.6%;HR 0.34;95%CI 0.16-0.73;p=0.008). The incidence of AF lasting >;24 hours was also significantly lower with LBBAP compared with BVP (0.7% vs 2.9%;p=0.015). <b>Conclusions:</b> LBBAP was associated with lower incidence of sustained VT/VF and new-onset AF compared with BVP. This difference remained significant after adjustment for differences in baseline characteristics between patients with BVP and LBBAP. Physiologic resynchronization by LBBAP may be associated with lower risk of arrhythmias compared with BVP.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950738</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067465>10.1161/CIRCULATIONAHA.123.067465</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950738</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Bengt Herweg</dc:creator><dc:creator> Parikshit S Sharma</dc:creator><dc:creator> Oscar Cano</dc:creator><dc:creator> Shunmuga Sundaram Ponnusamy</dc:creator><dc:creator> Francesco Zanon</dc:creator><dc:creator> Marek Jastrzebski</dc:creator><dc:creator> Jiangang Zou</dc:creator><dc:creator> Mihail G Chelu</dc:creator><dc:creator> Kevin Vernooy</dc:creator><dc:creator> Zachary I Whinnett</dc:creator><dc:creator> Girish M Nair</dc:creator><dc:creator> Manuel Molina-Lerma</dc:creator><dc:creator> Karol Curila</dc:creator><dc:creator> Dipen Zalavadia</dc:creator><dc:creator> Cicely Dye</dc:creator><dc:creator> Sharath C Vipparthy</dc:creator><dc:creator> Ryan Brunetti</dc:creator><dc:creator> Mishal Mumtaz</dc:creator><dc:creator> Pawel Moskal</dc:creator><dc:creator> Andrew M Leong</dc:creator><dc:creator> Antonius van Stipdonk</dc:creator><dc:creator> Jerin George</dc:creator><dc:creator> Yusuf K Qadeer</dc:creator><dc:creator> Jeffrey Kolominsky</dc:creator><dc:creator> Mehrdad Golian</dc:creator><dc:creator> Ramez Morcos</dc:creator><dc:creator> Lina Marcantoni</dc:creator><dc:creator> Faiz A Subzposh</dc:creator><dc:creator> Kenneth A Ellenbogen</dc:creator><dc:creator> Pugazhendhi Vijayaraman</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> Circulation</dc:source><dc:title> Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS)</dc:title><dc:identifier> pmid:37950738</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067465</dc:identifier></item><item><title> Neutrophil counts and cardiovascular disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Observational and genetically determined high neutrophil counts were associated with atherosclerotic cardiovascular disease, supporting that high blood neutrophil counts is a causal risk factor for atherosclerotic cardiovascular disease. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 9:ehad649. doi: 10.1093/eurheartj/ehad649. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Anti-inflammatory trials have shown considerable benefits for cardiovascular disease. High neutrophil counts, an easily accessible inflammation biomarker, are associated with atherosclerosis in experimental studies. This study aimed to investigate the associations between neutrophil counts and risk of nine cardiovascular endpoints using observational and genetic approaches. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Observational studies were conducted in the Copenhagen General Population Study (n = 101 730). Genetic studies were firstly performed using one-sample Mendelian randomization (MR) with individual-level data from the UK Biobank (n = 365 913); secondly, two-sample MR analyses were performed using summary-level data from the Blood Cell Consortium (n = 563 085). Outcomes included ischaemic heart disease, myocardial infarction, peripheral arterial disease, ischaemic cerebrovascular disease, ischaemic stroke, vascular-related dementia, vascular dementia, heart failure, and atrial fibrillation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Observational analyses showed associations between high neutrophil counts with high risks of all outcomes. In the UK Biobank, odds ratios (95% confidence intervals) per 1-SD higher genetically predicted neutrophil counts were 1.15 (1.08, 1.21) for ischaemic heart disease, 1.22 (1.12, 1.34) for myocardial infarction, and 1.19 (1.04, 1.36) for peripheral arterial disease; similar results were observed in men and women separately. In two-sample MR, corresponding estimates were 1.14 (1.05, 1.23) for ischaemic heart disease and 1.11 (1.02, 1.20) for myocardial infarction; multiple sensitivity analyses showed consistent results. No robust associations in two-sample MR analyses were found for other types of leucocytes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Observational and genetically determined high neutrophil counts were associated with atherosclerotic cardiovascular disease, supporting that high blood neutrophil counts is a causal risk factor for atherosclerotic cardiovascular disease.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950632</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad649>10.1093/eurheartj/ehad649</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950632</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Jiao Luo</dc:creator><dc:creator> Jesper Qvist Thomassen</dc:creator><dc:creator> Børge G Nordestgaard</dc:creator><dc:creator> Anne Tybjærg-Hansen</dc:creator><dc:creator> Ruth Frikke-Schmidt</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> Neutrophil counts and cardiovascular disease</dc:title><dc:identifier> pmid:37950632</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad649</dc:identifier></item><item><title> Timing treatment for tricuspid regurgitation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 9:ehad768. doi: 10.1093/eurheartj/ehad768. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950518</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad768>10.1093/eurheartj/ehad768</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950518</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Kush P Patel</dc:creator><dc:creator> Andreas Baumbach</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> Timing treatment for tricuspid regurgitation</dc:title><dc:identifier> pmid:37950518</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad768</dc:identifier></item><item><title> A fish bone wandering in the body</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950498/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 9:ehad754. doi: 10.1093/eurheartj/ehad754. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950498/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950498</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad754>10.1093/eurheartj/ehad754</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950498</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Yiyuan Li</dc:creator><dc:creator> Qiang Guo</dc:creator><dc:creator> Bin Huang</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> A fish bone wandering in the body</dc:title><dc:identifier> pmid:37950498</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad754</dc:identifier></item><item><title> Interplay between coronary bridging and high shear stress in the emergence of coronary vasospasm</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950497/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 9:ehad762. doi: 10.1093/eurheartj/ehad762. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950497/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950497</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad762>10.1093/eurheartj/ehad762</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950497</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Tijn PJ Jansen</dc:creator><dc:creator> Jolanda J Wentzel</dc:creator><dc:creator> Peter Damman</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> Interplay between coronary bridging and high shear stress in the emergence of coronary vasospasm</dc:title><dc:identifier> pmid:37950497</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad762</dc:identifier></item><item><title> A rare septal diverticulum found in a dilated cardiomyopathy: guilty or innocent?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231112193932&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 9:ehad759. doi: 10.1093/eurheartj/ehad759. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231112193932&v=2.17.9.post6+86293ac">37950453</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad759>10.1093/eurheartj/ehad759</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950453</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Ting Liu</dc:creator><dc:creator> Lokyi Tsang</dc:creator><dc:creator> Qing Zhang</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> A rare septal diverticulum found in a dilated cardiomyopathy: guilty or innocent?</dc:title><dc:identifier> pmid:37950453</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad759</dc:identifier></item></channel></rss>